Pharmacokinetics of-reductase inhibitor

- Jul 12, 2017 -

To date, only the pharmacokinetic reports of these agents have been seen in public, with a detailed pharmacokinetic data of lovastatin. It is taken in the form of an inactive lactone, which is rapidly converted into an active drug in the liver. Its main active metabolites, in addition to this?-hydroxy acid, there are 6-hydroxy derivatives and other two kinds of not identified metabolites. The main pathway for the excretion of lovastatin and its metabolites is the small intestine. Whether it is caused by absorption, or after absorption of the secretion into the bile, are discharged from the intestinal tract. Less than 10% of lovastatin is excreted by urine. In plasma, these products are combined with proteins. Lovastatin is discharged from the liver into bile. The ability of the liver to secrete in part depends on the concentration of the drug in the plasma.

In animal experiments, single dose lovastatin only absorbed 30%. When the liver is first passed, almost all the drugs are ingested. It appears that less than a doses of oral dose of 5% enter the body circulation. This shows that the main role of lovastatin is the liver, may also have a role in the small intestine. Its interaction with other drugs has not yet been well studied. The use of lovastatin in the human body does not affect the pharmacokinetics of an aspirin (antipyrine). This suggests that the drug does not affect the cytochrome P-450 system.